|Bid||1.2200 x 1300|
|Ask||1.3400 x 1100|
|Day's Range||1.2500 - 1.3800|
|52 Week Range||0.6200 - 7.3500|
|Beta (5Y Monthly)||0.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 07, 2022 - Dec 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
STONY BROOK, N.Y. & ITHICA, N.Y., September 08, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine ("CUCVM") announced the signing of a research agreement (the "Agreement") to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications. Primarily, the Agreement seeks to combine LinearD
STONY BROOK, N.Y., September 07, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
STONY BROOK, N.Y., September 06, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.